LZLing Zhao

Ling Zhao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ling Zhao has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Yumeng Wei

    Department of Pharmaceutics, School of Pharmacy, Luzhou Medical College , Luzhou City, Sichuan Province , P.R. China

    2 shared publications
  • Wei Li

    Chongqing Pharmaceutical Engineering Research Center, College of Pharmacy, Chongqing Medical University, Chongqing, P.R. China

    1 shared publication
  • Xiaodong Zhong

    Chongqing Pharmaceutical Engineering Research Center, College of Pharmacy, Chongqing Medical University, Chongqing, P.R. China

    1 shared publication
  • Ya Wang

    Chongqing Pharmaceutical Engineering Research Center, College of Pharmacy, Chongqing Medical University, Chongqing, P.R. China

    1 shared publication
  • Yu Liu

    Chongqing Pharmaceutical Engineering Research Center, College of Pharmacy, Chongqing Medical University, Chongqing, P.R. China

    1 shared publication
  • Yu Yu

    Key Laboratory for Biochemistry and Molecular Pharmacology of Chongqing, Department of Medicinal Chemistry, School of Pharmacy, Chongqing Medical University

    1 shared publication

Latest Publications

  • Passive lung-targeted drug delivery systems via intravenous administration

    by Yumeng Wei, Ling Zhao

    The treatment of lung diseases including lung cancer and tuberculosis is one of the most challenging problems in clinical practice, because the conventional drug delivery systems cannot deliver drug effectively to the lung, which result in low therapeutic effect. Therefore, lung-targeted drug delivery systems (LTDDS) that can deliver drug to the lung in an effective way to increase drug concentration in lung tissue and reduce drug distribution in other organs and tissues become an ideal strategy to treat lung diseases. The LTDDS mainly include microparticles (microspheres and microencapsules), liposomes and nanoparticles via intravenous administration, and dry powder carriers and nebulized suspensions via pulmonary inhalation. As lungs possess the large absorptive surface area, the low thickness of the epithelial barrier and good blood supply, pulmonary inhalation has received great attention. Intravenous route is the commonly practiced method for administration of larger doses of drugs into the body. Numerous drugs can be delivered directly into general circulation by avoiding their first-pass metabolism and have potential to transport drugs to the lung via intravenous administration. This present article reviews the development, evaluation and application of LTDDS via intravenous administration for the treatment of lung diseases reported in the past decades.


  • Solid dispersion and effervescent techniques used to prepare docetaxel liposomes for lung-targeted delivery system:in vitroandin vivoevaluation

    by Ling Zhao, Yumeng Wei, Wei Li, Yu Liu, Ya Wang, Xiaodong Zhong, Yu Yu

    A lung-targeting liposomal docetaxel was developed to improve therapeutic index and to reduce side effects. Docetaxel proliposomes composed of docetaxel/Tween-80/Phospholipon 90H/cholesterol/citric acid at molar ratio of 0.18:0.09:3.78:3.78:91.17 were prepared by solid dispersion technique, and then were hydrated with NaHCO3 solution to obtain docetaxel liposomes by effervescent technique. The stability of proliposomes containing docetaxel, characterization and evaluation of lung-targeting effect of docetaxel liposomes in rabbit were studied. Docetaxel proliposomes were stable at 6 ± 2°C for at least 12 months. The particle size, zeta-potential, and entrapment efficiency of the resulted liposomes were 1011 ± 22 nm, −23.7 ± 0.26 mv, and 90.12 ± 0.36%, respectively. As far as the targeting parameters are concerned, the relative intake rate (Re) and the ratio of peak concentration (Ce) of lung were 28.91 and 74.28, respectively. Compared with liver, spleen, and kidney, the ratios of targeting efficacy (Te)liposomes to (Te)injection of lung were increased by a factor of 3.16, 23.00, and 27.83, respectively. In conclusion, the negatively charged docetaxel liposomes with diameter of about 1 µm described in this study have favorable lung-targeting effect and are a promising lung-targeting carrier.


  • In vitro and in vivo evaluation of ranitidine hydrochloride loaded hollow microspheres in rabbits

    by Yu-Meng Wei, Ling Zhao

    The objective of this investigation was to develop the hollow microspheres as a new dosage form of floating drug delivery systems with prolonged stomach retention time. Hollow microspheres containing ranitidine hydrochloride (RH) were prepared by a novel solvent diffusion-evaporation method using ethyl cellulose (EC) dissolved in a mixture of ethanol and ether (6:1.0, v/v). The yield and drug loading amount of hollow microspheres were 83.21±0.28% and 20.71±0.32%, respectively. The in vitro release profiles showed that the drug release rate decreased with increasing viscosity of EC and the diameter of hollow microspheres, while increased with the increase of RH/EC weight ratio. Hollow microspheres could prolong drug release time (approximately 24 h) and float over the simulate gastric fluid for more than 24 h. Pharmacokinetic analysis showed that the bioavailability from RH-hollow microspheres alone was about 3.0-times that of common RH gelatin capsules, and it was about 2.8-times that of the solid microspheres. These results demonstrated that RH hollow microspheres were capable of sustained delivery of the drug for longer period with increased bioavailability.